Encoded Therapeutics has secured a $275 million Series F to advance its lead genetic medicine ETX101 for Dravet syndrome into broader clinical development and to scale internal manufacturing. The company is using the capital to fund studies required for continued trial readiness and manufacturing buildout. The financing also positions a second asset, ETX301, for a planned 2027 investigational new drug (IND) filing, expanding the company’s pipeline beyond epilepsy. The round included GV and a syndicate of biotech-focused investors, reflecting market appetite for vertically integrated gene therapy platforms. For the sector, the deal underscores how rare-disease genetics companies are funding both clinical programs and manufacturing capability at the same time to improve execution speed and control.